« Arsenic Bacteria Ride Again. (Or Don't). |
| The Key to Everything? Not Quite. »
January 27, 2012
Roche Goes Hostile for Illumina
Roche is not only a big drug company, it's a big diagnostics company. And that's what's driving their unsolicited bid for Illumina, a gene-sequencing company from San Diego. Illumina has been one of the big players in the "How quickly and cheaply can we sequence a person's entire genome" game, and apparently Roche believes that there's something in it for them.
But as that Reuters link above shows, a lot of other people don't agree, and would rather partner than acquire (Chris Viehbacher, CEO of Sanofi, seems to have been waiting for the opportunity to unburden himself of thoughts to that effect). He may well be right. Sequencing has been a can-you-top-this field for some time, and I don't think that the process is finished yet. What if you buy a technology that's superseded before it has the time to pay off? What if the market for sequencing doesn't get as large, as quickly, as you're hoping? Those were Illumina's worries, and now they're going to be Roche's; you can't buy the promise without buying those, too.
Matthew Herper at Forbes is having very similar thoughts, and points out that Roche has done this sort of thing before. For now, we'll see what Illumina might be able to come up with to avoid being Roched.
+ TrackBacks (0) | Category: Biological News | Business and Markets
POST A COMMENT
- RELATED ENTRIES
- What Structures Have Turned on You?
- K. C. Nicolaou on Drug Discovery
- The Prospects of an Academic Job
- Targacept Fumbles the Bad News on Alzheimer's
- Modifying Red Blood Cells As Carriers
- How to Run a Drug Project: Are There Any Rules at All?
- Employment Among New Chemistry PhDs
- My Imaginary Friends Would Be Glad to Serve as Referees